These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8140182)

  • 1. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup.
    Cottraux J; Mollard E; Bouvard M; Marks I
    Psychiatry Res; 1993 Oct; 49(1):63-75. PubMed ID: 8140182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder.
    Cottraux J; Mollard E; Bouvard M; Marks I; Sluys M; Nury AM; Douge R; Cialdella P
    Int Clin Psychopharmacol; 1990 Jan; 5(1):17-30. PubMed ID: 2110206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.
    Rufer M; Hand I; Alsleben H; Braatz A; Ortmann J; Katenkamp B; Fricke S; Peter H
    Eur Arch Psychiatry Clin Neurosci; 2005 Apr; 255(2):121-8. PubMed ID: 15812606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up.
    van Oppen P; van Balkom AJ; de Haan E; van Dyck R
    J Clin Psychiatry; 2005 Nov; 66(11):1415-22. PubMed ID: 16420079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder.
    van Balkom AJ; de Haan E; van Oppen P; Spinhoven P; Hoogduin KA; van Dyck R
    J Nerv Ment Dis; 1998 Aug; 186(8):492-9. PubMed ID: 9717867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine treatment of obsessive-compulsive disorder.
    Perse TL; Greist JH; Jefferson JW; Rosenfeld R; Dar R
    Am J Psychiatry; 1987 Dec; 144(12):1543-8. PubMed ID: 3120604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine.
    Nakatani E; Nakagawa A; Nakao T; Yoshizato C; Nabeyama M; Kudo A; Isomura K; Kato N; Yoshioka K; Kawamoto M
    Psychother Psychosom; 2005; 74(5):269-76. PubMed ID: 16088264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
    Andersson E; Hedman E; Enander J; Radu Djurfeldt D; Ljótsson B; Cervenka S; Isung J; Svanborg C; Mataix-Cols D; Kaldo V; Andersson G; Lindefors N; Rück C
    JAMA Psychiatry; 2015 Jul; 72(7):659-67. PubMed ID: 25970252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.
    O'Sullivan G; Noshirvani H; Marks I; Monteiro W; Lelliott P
    J Clin Psychiatry; 1991 Apr; 52(4):150-5. PubMed ID: 2016246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study.
    Hohagen F; Winkelmann G; Rasche-Rüchle H; Hand I; König A; Münchau N; Hiss H; Geiger-Kabisch C; Käppler C; Schramm P; Rey E; Aldenhoff J; Berger M
    Br J Psychiatry Suppl; 1998; (35):71-8. PubMed ID: 9829029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
    Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy.
    Foa EB; Kozak MJ; Steketee GS; McCarthy PR
    Br J Clin Psychol; 1992 Sep; 31(3):279-92. PubMed ID: 1393157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder.
    Neziroglu F; Yaryura-Tobias JA; Walz J; McKay D
    J Child Adolesc Psychopharmacol; 2000; 10(4):295-306. PubMed ID: 11191690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
    Goodman WK; Price LH; Rasmussen SA; Delgado PL; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1989 Jan; 46(1):36-44. PubMed ID: 2491940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences between early and late drop-outs from treatment for obsessive-compulsive disorder.
    Aderka IM; Anholt GE; van Balkom AJ; Smit JH; Hermesh H; Hofmann SG; van Oppen P
    J Anxiety Disord; 2011 Oct; 25(7):918-23. PubMed ID: 21664103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
    Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of course in obsessive-compulsive disorder: logistic regression versus Cox regression for recurrent events.
    Kempe PT; van Oppen P; de Haan E; Twisk JW; Sluis A; Smit JH; van Dyck R; van Balkom AJ
    Acta Psychiatr Scand; 2007 Sep; 116(3):201-10. PubMed ID: 17655562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.